Currently, three BRAF inhibitors have been approved by the FDA for combination use with MEK inhibitors in the treatment of melanoma—vemurafenib plus cobimetinib, dabrafenib plus trametinib, and encorafenib plus binimetinib; among them, dabrafenib plus trametinib was the first combination approved by the FDA.75, 79, 80. This evidence concerns the gene BRAF and melanoma.